Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 5Phase 3 3Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Lung Cancer 1Solid Tumors 1Breast Neoplasms 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Completed × iniparib × Clear all
NCT01593228 2017-09-19

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Sanofi

Phase 3 Completed
37 enrolled
Other solid neoplasm

Solid Tumors

NCT01082549 2016-03-17

ECLIPSE

Sanofi

Phase 3 Completed
780 enrolled
Thoracic

Squamous Cell Lung Cancer

NCT00938652 2013-09-19

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Sanofi

Phase 3 Completed
519 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡